newsfilter
← Latest News
GlobeNewswire·

Achilles Therapeutics Presents Positive Data at ESMO I-O Congress 2021 on High-Dose Manufacturing Process for Precision T Cell Therapies Targeting Clonal Neoantigens

-Over 10-fold dose increase at GMP scale with VELOS™ Process 2 manufacturing- -cNeT maintain CD4+ and CD8+ T cell subsets with a highly potent polyclonal phenotype- -Dosing of patients with high-dose cNeT expected in 1H 2022- LONDON, Dec